On August 29, 2023, the U.S. Department of Health and Human
Services (HHS) issued a letter formally recommending the U.S. Drug
Enforcement Administration (DEA) re-classify cannabis from a
Schedule I Controlled Substance to a Schedule III Controlled
Substance under the federal Controlled Substances Act.
Schedules
Since the founding of the DEA in 1970, cannabis has been listed
as a Schedule I substance. Under federal law, Schedule I drugs are
defined as having “no currently accepted medical use and a
high potential for abuse.” Along with cannabis, other
Schedule I drugs include heroin and LSD.
Under federal law, Schedule III drugs are defined as having
“moderate to low potential for physical and psychological
dependence.” Schedule III drugs include ketamine, anabolic
steroids, and testosterone.